Key Points {#FPar1}
==========

Oral insulin 338 is a long-acting, basal insulin formulated in a Gastro-Intestinal Permeation Enhancement Technology One (GIPET^®^ I) tablet with the absorption enhancer sodium caprate. The effect of timing of food intake on the pharmacokinetics of oral insulin 338 was investigated in healthy males.Absorption of oral insulin 338 was reduced by \~ 65% when a meal was consumed immediately after dosing, while absorption of oral insulin 338 was comparable when the same meal was given 30, 60 or 360 min post-dose. Oral insulin 338 was well-tolerated in this trial.Patients with diabetes mellitus do not need to wait more than 30 min before eating their breakfast after a morning dose of oral insulin 338, which is considered relevant for patient convenience and treatment compliance.

Introduction {#Sec1}
============

Over nearly a century, several attempts have been made to develop insulin for oral administration to patients with diabetes mellitus. Potential advantages of oral insulin delivery, as compared to subcutaneous injection, include improved patient convenience and compliance, and a more physiological insulin profile through a higher portal-to-peripheral insulin gradient. The latter has the potential to reduce diabetes adverse effects such as hypoglycaemia, weight gain, neuropathy and retinopathy \[[@CR1]--[@CR4]\]. The main challenge to oral insulin delivery is that systemic absorption of orally administered protein-based drugs is hindered by their vulnerability to proteolytic degradation in the gastrointestinal tract and by their low intestinal permeability \[[@CR5], [@CR6]\].

Since oral insulin is absorbed relatively fast from the gastrointestinal tract, the rate of systemic appearance of orally administered insulin is high relative to subcutaneously administered insulin. This is probably the reason why oral insulin has always been considered a potential mealtime insulin \[[@CR3]\]. However, specific considerations exist for an oral mealtime insulin, such as the variability of insulin exposure after oral administration and the potential effect of food on insulin absorption. These particular challenges may be less relevant for an oral basal insulin.

Oral insulin 338 is a novel tablet formulation of a long-acting basal insulin formulated in a Gastro-Intestinal Permeation Enhancement Technology One (GIPET^®^ I) tablet with the absorption enhancer sodium caprate \[[@CR7]\]. Insulin 338 has been modified compared to human insulin in order to make it more resistant to enzymatic degradation in the gastrointestinal tract, while acylation of insulin 338 causes reversible binding to albumin, resulting in a plasma half-life of up to 70 h at steady state \[[@CR8]\]. Sodium caprate is approved by the US Food and Drug Administration (FDA) as a food additive for human consumption with no limit for daily intake set by the World Health Organization \[[@CR9]\]. The absorption enhancement by sodium caprate is believed to occur via tight junction modulation and cell membrane fluidisation, thus acting on both paracellular and transcellular pathways \[[@CR9]\].

As already mentioned, absorption of orally administered drugs may be affected by food ingestion \[[@CR10]\]. Therefore, it is crucial to evaluate the effect of food on the pharmacokinetics of drugs intended to be administered via the oral route \[[@CR11], [@CR12]\]. Accordingly, the rationale for the present trial was to investigate the effect of timing of post-dose food intake on the single-dose pharmacokinetic properties of oral insulin 338 in healthy subjects.

Methods {#Sec2}
=======

Trial Design and Subjects {#Sec3}
-------------------------

This was a randomised, single-centre (Profil, Neuss, Germany), open-label, four-period crossover trial (Electronic Supplementary Material Online Resource 1, Fig. S1). The trial protocol was reviewed and approved by the local health authorities (Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn, Germany) and an independent ethics committee (Ethik-Kommission der Ärztekammer Nordrhein, Düsseldorf, Germany).

Eligible subjects were healthy men 18--64 years of age (both inclusive) with a body mass index (BMI) of 18.5--28.0 kg/m^2^ (both inclusive). Exclusion criteria included clinically significant concomitant diseases (including acute or chronic gastrointestinal symptoms), clinically significant abnormal values in clinical laboratory screening tests (including a fasting plasma glucose ≥ 5.6 mmol/L), previous clinically significant gastrointestinal surgery, smoking (defined as \> 5 cigarettes or the equivalent per day), or use of prescription or non-prescription medication within 2 weeks prior to first dosing (occasional use of paracetamol and acetylsalicylic acid \[aspirin\] was permitted up to 48 h prior to dosing).

Trial Procedures and Assessments {#Sec4}
--------------------------------

The trial consisted of seven visits: an informed consent visit, a screening visit, four dosing visits separated by 7--15 days' washout (from last pharmacokinetic sampling until next dosing) and a follow-up visit.

At each dosing visit, subjects attended the clinical site in the evening on the day prior to dosing. Subjects were asked not to smoke, perform strenuous physical exercise, take any prescription or non-prescription medication, including routine vitamins, or to consume alcohol, excessive amounts of coffee or tea (\> 5 cups per day), other xanthine-containing beverages or chocolate during the last 48 h prior to dosing. Subjects received a standardised dinner and subsequently fasted overnight (from 22:00 h).

In the morning of the dosing day at approximately 08:00 h, subjects received a single fixed oral dose of insulin 338 (8100 nmol; Novo Nordisk, Bagsværd, Denmark) formulated in a film coated (Opadry^®^ II Yellow) GIPET^®^ I tablet with the absorption enhancer sodium caprate (550 mg). The tablet was administered with 100 mL still water. No other water consumption was allowed from 1 h before dosing until 1 h after dosing. Subjects were dosed in a semi-supine position and were not allowed to lie supine for the first 2 h post-dose except for trial procedures.

A test meal was served either at 0, 30, 60 or 360 min after dosing. The composition of the test meal was identical at all dosing visits. The post-dose test meal consisted of chicken with whole grain pasta and tomato sauce plus a dessert of apple--strawberry compote with cottage cheese. This mixed meal with fixed energy content (approximately 500 kcal) contained approximately 57 energy percent (E%) carbohydrate, 13 E% fat and 30 E% protein. For the 0 min post-dose fasting, ingestion of the post-dose test meal was initiated immediately after dosing. Independent of the post-dose fasting period, the entire meal had to be ingested within 15 min. The 0 and 360 min post-dose fasting periods corresponded to the fed and fasted conditions, respectively, and were hypothesised to represent the lower and upper limits of exposure. The 30 and 60 min post-dose fasting periods were included to evaluate two clinically feasible intervals in case of morning dose administration.

From dosing until 360 min post-dose, subjects were not allowed to eat any foods except for the standardised post-dose test meal. Subjects were allowed to drink up to 500 mL of water from 60 to 360 min post-dose. For the 0, 30 and 60 min post-dose fasting, subjects were served standardised meals at 360 min (identical to the post-dose test meal) and 12 h (standardised dinner). With respect to 360 min post-dose fasting, subjects were only served the post-dose test meal at 360 min and a standardised dinner at 12 h. Subjects stayed in-house at the clinical site until 48 h after dosing for safety observation and pharmacokinetic blood sampling. From 12 to 48 h after dosing, subjects were served meals (breakfast, lunch, dinner and snacks) at appropriate timepoints during the in-house stay and no other food intake was allowed. The subjects attended the clinical site for short visits at 72, 96, 120, 168, 216 and 288 h post-dose for pharmacokinetic blood sampling (Online Resource 1, Table S1).

Serum insulin 338 concentrations were measured by a validated insulin 338-specific luminescent oxygen channelling immunoassay (LOCI) with a lower limit of quantification (LLOQ) of 200 pmol/L. Serum capric acid concentrations were measured by a validated chromatographic assay with an LLOQ of 100 ng/mL.

Safety assessments included adverse events (AEs), hypoglycaemic episodes (classified according to the American Diabetes Association \[[@CR13]\]), laboratory safety parameters, physical examination, vital signs and electrocardiogram.

Trial Endpoints {#Sec5}
---------------

Insulin 338 pharmacokinetic endpoints were total exposure (area under the concentration--time curve \[AUC\] from time zero to infinity \[AUC~Ins338,0--∞~\]; primary endpoint), maximum concentration (*C*~max,Ins338~), time from dosing until the first time that serum insulin 338 concentration was above LLOQ (onset of appearance~Ins338~), time to maximum concentration (*t*~max,Ins338~) and terminal half-life (*t*~½,Ins338~).

AUC~Ins338,0--∞~ was calculated as the sum of the AUC from dosing until the time of last quantifiable insulin 338 concentration (using the linear trapezoidal technique) and the AUC from the time of last quantifiable insulin 338 concentration derived by extrapolation until infinity based on the terminal slope. *t*~½,Ins338~ was calculated as log(2)/*λ*~*z*~, where *λ*~*z*~ is the terminal rate constant determined by linear regression on the terminal part of the serum insulin 338 concentration--time profiles.

Capric acid pharmacokinetic endpoints were the exposure from 0 to 360 min (AUC~Capric\ acid,0--360min~; calculated by the linear trapezoidal technique), maximum concentration (*C*~max,Capric\ acid~) and time to maximum concentration (*t*~max,Capric\ acid~).

Statistical Analyses {#Sec6}
--------------------

The sample size calculation was based on the precision of the ratio of AUC~Ins338,0--∞~ between any two post-dose fasting periods. Based on a previous trial with oral insulin 338, it was assumed that the within-subject standard deviation for AUC~Ins338,0--∞~ was 1.01 on a log scale. To obtain a probability of at least 80% that the 95% confidence interval (CI) for the true ratio of AUC~Ins338,0--∞~ between two post-dose fasting periods ranged from 0.62 to 1.61 times the observed estimate of the ratio, a total of 40 evaluable pharmacokinetic profiles for each of the four post-dose fasting periods were needed. In order to account for dropouts, it was planned to randomise 45 subjects.

Statistical analyses were performed using SAS^®^ version 9.4 (SAS Institute, Cary, NC, USA) at a 5% significance level based on all randomised subjects receiving at least one dose of trial product.

In order to compare the effect of post-dose fasting duration on the pharmacokinetics of insulin 338, AUC~Ins338,0--∞~ and *C*~max,Ins338~ were analysed in a linear mixed model with the log-transformed endpoint as dependent variable, post-dose fasting period and trial period as fixed effects and subject as a random effect. The model also included residual variance depending on the post-dose fasting period. From the model, mean differences between post-dose fasting periods in the log-transformed endpoints were estimated and back-transformed to the original scale and presented as ratios together with corresponding two-sided 95% CIs. Specifically, the three shorter post-dose fasting periods were compared with 360 min of post-dose fasting, since 360 min of post-dose fasting was expected to result in the greatest insulin 338 absorption due to expected complete or near complete insulin 338 absorption within 360 min after oral dosing.

In order to estimate and compare the total pharmacokinetic variability between each of the four post-dose fasting periods, the total variability in AUC~Ins338,0--∞~ and *C*~max,Ins338~ was estimated for each of the four post-dose fasting periods in the model described. Total variability consisted of both the within-subject day-to-day variability and the between-subject variability. It was tested by a likelihood ratio test whether the model with different variances for the four post-dose fasting periods could be reduced to a model with a common variance for all four post-dose fasting periods, suggesting no difference in variance among the four post-dose fasting periods.

All other pharmacokinetic endpoints for insulin 338 and capric acid as well as all safety endpoints were summarised by descriptive statistics based on all subjects receiving at least one dose of trial product.

Results {#Sec7}
=======

Subjects {#Sec8}
--------

Of 56 subjects screened, 45 were randomised, 44 were treated and 42 completed the trial. One subject withdrew consent before dosing at the first dosing visit, and one subject withdrew consent after completion of one trial period (60 min post-dose fasting). Furthermore, one subject was withdrawn due to an AE of increased blood creatine kinase-MB (CK-MB) with onset 12 days after dosing in the first trial period (30 min post-dose fasting), indicating non-compliance with the requirement to avoid strenuous physical exercise.

The mean (± standard deviation) age of the 44 exposed subjects was 34.7 (± 8.2) years. All subjects were white, mean body weight was 79.1 (± 8.8) kg and mean BMI was 24.2 (± 1.9) kg/m^2^.

Pharmacokinetics of Insulin 338 {#Sec9}
-------------------------------

Insulin 338 pharmacokinetic mean profiles were comparable for post-dose fasting periods of 30, 60 and 360 min (Fig. [1](#Fig1){ref-type="fig"} and Online Resource 1, Fig. S2) and there were no significant differences in AUC~Ins338,0--∞~ and *C*~max,Ins338~ for 30 and 60 min post-dose fasting compared with 360 min post-dose fasting (Fig. [2](#Fig2){ref-type="fig"}). The 0 min post-dose fasting resulted in generally lower mean exposure of insulin 338 (Fig. [1](#Fig1){ref-type="fig"} and Online Resource 1, Fig. S2), with a significant reduction of \~ 65% in AUC~Ins338,0--∞~ and *C*~max,Ins338~ compared with 360 min post-dose fasting (Fig. [2](#Fig2){ref-type="fig"}).Fig. 1Mean serum insulin 338 concentration--time profiles after oral administration and varying duration of post-dose fasting in healthy males. Error bars show standard error of the meanFig. 2Effect of post-dose fasting period on (**a**) AUC~Ins338,0--∞~ and (**b**) *C*~max,Ins338~ after oral administration of insulin 338 in healthy males. Bars are estimated means and 95% CIs. Treatment comparisons show estimated treatment ratios \[95% CI\] and *p* value for the pairwise comparisons of 0, 30 and 60 min post-dose fasting with 360 min post-dose fasting. *AUC*~*Ins338,0--∞*~ area under the concentration--time curve for insulin 338 from time zero to infinity, *CI* confidence interval, *C*~*max,Ins338*~ maximum concentration of insulin 338

The median onset of appearance~Ins338~ was 10 min independent of post-dose fasting period, while *t*~max,Ins338~ appeared to be shorter with a median of 25 min for the 0 min post-dose fasting compared with a median of 40--60 min for the 30, 60 and 360 min post-dose fasting periods (Table [1](#Tab1){ref-type="table"}). Harmonic mean *t*~½,Ins338~ ranged between 54.5 and 55.5 h for the four different post-dose fasting periods.Table 1Summary of onset of appearance~Ins338~ and *t*~max,Ins338~ after an oral single dose of insulin 338 and varying duration of post-dose fasting in healthy male subjectsEndpointPost-dose fasting period0 min30 min60 min360 minOnset of appearance~Ins338~ (min) Geometric mean8.69.39.49.5 CV%36.023.230.222.8 Median10.010.010.010.0 Min--Max5.0--20.05.0--15.05.0--15.05.0--15.0*t*~max,Ins338~ (min) Geometric mean25.241.655.046.3 CV%64.828.033.346.3 Median25.040.060.045.0 Min--Max15.0--75.025.0--90.025.0--90.020.0--135.0*CV%* percentage coefficient of variation, *Max* maximum, *Min* minimum, *Onset of appearance*~*Ins338*~ time from dosing until the first time that serum insulin 338 concentration was above lower limit of quantification, *t*~*max,Ins338*~ time to maximum concentration for insulin 338

For AUC~Ins338,0--∞~, the coefficient of variation for the total variability ranged from 82.4% to 131.5% for the four post-dose fasting periods (Online Resource 1, Table S2). The model with different variance for each post-dose fasting period could be reduced to a model with a common variance for the four post-dose fasting periods (*p* = 0.112), suggesting that the total variability in AUC~Ins338,0--∞~ did not differ between post-dose fasting periods. For *C*~max,Ins338~, the coefficient of variation for the total variability was 122.2%, 163.2%, 90.0% and 84.5% for 0, 30, 60 and 360 min post-dose fasting, respectively (Online Resource 1, Table S2). The model with different variance for each post-dose fasting period could not be reduced (*p* = 0.006), suggesting that the total variability in *C*~max,Ins338~ differed between the four post-dose fasting periods.

Pharmacokinetics of Capric Acid {#Sec10}
-------------------------------

Capric acid pharmacokinetic profiles are shown for the four different post-dose fasting periods in Online Resource 1, Fig. S3. Compared to insulin 338, capric acid was rapidly eliminated. Mean serum capric acid concentrations were at the usual baseline level from \~ 2 h after dosing. The capric acid pharmacokinetic profile was slightly left-shifted for 0 min post-dose fasting compared with 30, 60 and 360 min post-dose fasting. Accordingly, *C*~max,Capric acid~ appeared to be higher and *t*~max,Capric acid~ appeared to be shorter with 0 min post-dose fasting than with longer post-dose fasting periods. There were only minor differences in the AUC for capric acid from time zero to 6 h (AUC~Capric\ acid,0--6h~) between the four post-dose fasting periods (Online Resource 1, Table S3).

Safety {#Sec11}
------

Oral administration of an insulin 338 tablet was well-tolerated with no safety issues identified during the trial. A total of 42 AEs were reported in 25 subjects (57%). No apparent differences in number of AEs were observed between the four post-dose fasting periods (8, 10, 11 and 13 events with 0, 30, 60 and 360 min post-dose fasting, respectively). All AEs were non-serious, and all AEs were either mild (6, 7, 9 and 12 events) or moderate (2, 3, 2 and 1 events) in severity and either unlikely related (6, 7, 7 and 9 events) or possibly related (2, 3, 4 and 4 events) to trial product. The most frequently reported AEs were headache (2, 2, 5 and 4 events) and nasopharyngitis (4, 0, 3 and 2 events). All subjects recovered from the AEs. One AE (increased blood CK-MB with onset 12 days after last dosing) led to withdrawal of the subject.

A total of 90 hypoglycaemic episodes were reported in 25 subjects (56.8%). Fewer hypoglycaemic episodes were reported for 0 min post-dose fasting (13 episodes) than for longer post-dose fasting periods (26, 25 and 26 episodes for 30, 60 and 360 min post-dose fasting). During the first 360 min after dosing, 2, 9, 14 and 9 hypoglycaemic episodes were reported for 0, 30, 60 and 360 min post-dose fasting, respectively. The majority of hypoglycaemic episodes were asymptomatic (85 episodes), while 4 episodes were documented symptomatic and 1 episode was probably symptomatic. No severe hypoglycaemic episodes were reported.

There were no clinically significant findings in safety laboratory parameters, vital signs, physical examination or electrocardiogram.

Discussion {#Sec12}
==========

The main finding of the current trial was that the pharmacokinetic properties of insulin 338 were comparable for post-dose fasting periods of 30, 60 and 360 min, while a marked reduction in insulin 338 exposure of \~ 65% was seen with food ingestion immediately after dosing compared with 360 min after dosing. A previous trial investigating the effect of post-dose fasting period on the pharmacokinetics of orally administered mealtime insulin showed no difference in insulin exposure between post-dose fasting periods of 10, 45 or 90 min \[[@CR14]\]. On the other hand, studies with oral administration of other peptide drugs have shown that no or limited post-dose fasting reduced the systemic drug absorption \[[@CR15]--[@CR17]\]. Meal ingestion 10 min after oral dosing of salmon calcitonin co-formulated with 5-CNAC \[8-(N-2-hydroxy-5-chlorobenzoyl)-amino-caprylic acid\] reduced the exposure of salmon calcitonin by up to 30% versus 60 min post-dose fasting and by 41% versus 4 h post-dose fasting \[[@CR15], [@CR16]\]. Increasing post-dose fasting periods of 15, 30, 60 and 120 min following oral administration of semaglutide co-formulated with SNAC {sodium N-(8-\[2-hydroxybenzoyl\] amino) caprylate} were associated with increasing semaglutide exposure \[[@CR17]\]. In contrast to mealtime insulin, the therapeutic effect of basal insulin is not highly dependent on the timing of dosing relative to meal ingestion. Therefore, it is also less relevant for an oral basal insulin such as oral insulin 338, as compared with an oral mealtime insulin, to avoid any effect of food intake immediately after dosing on the insulin absorption from the gastrointestinal tract. In the current trial, meal ingestion immediately after oral dosing resulted in shorter *t*~max,Ins338~, suggesting that insulin 338 absorption was affected by the post-dose meal. Thus, the current results indicate that food intake shortly after oral insulin 338 administration should be avoided in order not to compromise insulin 338 serum exposure levels. Importantly, *t*~½,Ins338~ was unaffected by the post-dose fasting period, suggesting that the metabolism and elimination of insulin 338 are not affected by post-dose food intake.

Reduced exposure of oral insulin when administered close to a meal is one of the main reasons why several previous investigations of various oral insulin formulations have been conducted in a fasting condition \[[@CR18]--[@CR20]\]. However, studies of oral insulin formulations have also been performed in which insulin was administered together with a meal or only 10--20 min prior to meal ingestion, both with detectable exposure and glucose-lowering effect \[[@CR14], [@CR19], [@CR21]\]. Based on the current pharmacokinetic results, it would be recommended that patients with diabetes mellitus treated with oral insulin 338 as a basal insulin can have their breakfast 30 min after taking their once-daily dose of oral insulin 338 each morning. Such a dosing recommendation is considered to be feasible with respect to patient convenience and treatment compliance. Interestingly, another widely used drug, levothyroxine for the treatment of hypothyroidism, is also usually dosed in a fasting state ≥ 30 min prior to breakfast to ensure that food ingestion does not impair its absorption \[[@CR22]\].

The total variability in AUC~Ins338,0--∞~ and *C*~max,Ins338~ after oral insulin 338 administration was found to be within the range of 82--132% and 84--163%, respectively, for the coefficient of variation. This may seem to be high, and is indeed higher than seen for an oral human insulin product in subjects with type 2 diabetes with a variability in absorption of 60--70% for the coefficient of variation \[[@CR23]\]. However, in the previous study, pharmacokinetic measures included both exogenous human insulin and endogenous insulin, which may have reduced the measured pharmacokinetic variability \[[@CR23]\]. It is also important to note that the current trial was a single-dose trial, while the intended dosing regimen for oral insulin 338 is regular once-daily dosing. Due to its extended half-life, once-daily dosing of oral insulin 338 implies that the exposure from sequential daily doses will overlap. This will in turn reduce the day-to-day variability in exposure and, therefore, also the total variability. Accordingly, a phase II trial in subjects with type 2 diabetes showed that once-daily oral insulin 338 treatment for 8 weeks improved glycaemic control to an extent not different from that seen with 8 weeks of once-daily insulin glargine \[[@CR8]\]. The total variability in insulin 338 exposure increased with a decreasing post-dose fasting period, although it was only significant for *C*~max,Ins338~. The total variability in exposure associated with administering oral insulin 338 within 30 min prior to food intake does not, however, seem to be extreme and should therefore not exclude the dosing recommendation of taking the daily dose of oral insulin 338 at least 30 min prior to breakfast.

There were no unexpected safety findings in the present trial, and orally administered insulin 338 appeared to be safe in healthy male subjects. The observations of a numerically lower number of AEs and fewer hypoglycaemic episodes reported for 0 min post-dose fasting than for longer post-dose fasting periods were consistent with the lower level of insulin 338 exposure when food was ingested immediately after dosing.

Two important conclusions can be made based on the pharmacokinetic results for capric acid in the current trial. Firstly, elimination of capric acid occurred rapidly as mean serum capric acid concentrations had returned to the baseline level at approximately 2 h post-dose. Thus, once-daily dosing of oral insulin 338 with sodium caprate as an absorption enhancer will not lead to any build-up of circulating capric acid. Secondly, *C*~max,Capric acid~ was slightly higher and *t*~max,Capric acid~ was slightly shorter when subjects had their meal immediately after dosing of oral insulin 338 than after post-dose fasting periods of 30--360 min. This finding suggests that food can at least to some extent increase capric acid absorption from the gastrointestinal tract. It is tempting to speculate that due to increased capric acid absorption into the circulation, the smaller amounts of absorption enhancer left in the gastrointestinal tract might explain part of the reduced absorption of insulin 338 seen when food intake occurred immediately after oral insulin 338 administration. However, several in situ studies with sodium caprate on animal intestinal preparations suggest that close proximity as well as contemporaneous presence of promoter and candidate drug are more important for successful absorption enhancement than the exact local concentration of promoter \[[@CR9]\]. Therefore, an alternative explanation could be that presence of food in the gastrointestinal tract interferes with the close interaction of insulin 338 and sodium caprate and thereby leads to the large decrease seen in insulin 338 absorption following immediate food ingestion.

The current trial was conducted in accordance with relevant regulatory guidelines on food and drug interaction and bioequivalence \[[@CR11], [@CR12], [@CR24]\]. Thus, the trial was a single-dose trial. Due to the long half-life of oral insulin 338, the pharmacokinetic assessments after a single dose in the current trial may not be entirely reflective of the steady-state situation achieved with repeated once-daily administration in clinical practice. Still, differences or similarities in exposure of oral insulin 338 with varying post-dose fasting periods shown after a single dose should, at least in theory, be able to translate to the steady-state situation. A strength of the present trial was the specific pharmacokinetic measurement of exogenous insulin 338. Thus, current results on the absorption of insulin 338 after oral administration were not biased by any endogenous insulin secretion in the trial population of healthy subjects.

Finally, only males were recruited in the present trial as the preclinical reproduction toxicity studies with insulin 338 were not finalised at the time of trial conduct. It is, however, anticipated that the pharmacokinetic properties of oral insulin 338 in males do not differ from those in females, and furthermore that the pharmacokinetics of oral insulin 338 in healthy subjects are not markedly different from those in the target population of subjects with type 2 diabetes.

Conclusion {#Sec13}
==========

The present trial shows that absorption of oral insulin 338 administered in the fasting state is not affected by food intake from 30 min after dosing. This finding is important for patient convenience and treatment compliance, as it suggests that patients with diabetes mellitus can have their breakfast 30 min after their morning dose of basal oral insulin 338.
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